TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01412879
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01412879
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01412879
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT01412879
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03184870
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04029376
Drug: Iberogast®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
Study: NCT02993237
Drug: DRV/COBI FDC placebo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
Study: NCT02993237
Drug: D/C/F/TAF FDC placebo tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
Study: NCT01538771
Drug: Control Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
Study: NCT03368859
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT03368859
Drug: Fluorouracil - bolus
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT03368859
Drug: Fluorouracil - infusion
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT03368859
Drug: ABT-165
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous
Study: NCT00796718
Drug: Capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 825 milligrams per meter square (mg/m\^2) orally twice daily for 5 weeks.
Study: NCT02354833
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02266550
Drug: [14C] BILL 284 BS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00345605
Drug: Arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
Study: NCT02210780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An inactive substance containing no medicine administered via subcutaneous injection.
Study: NCT00003956
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003956
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06218901
Drug: immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06218901
Drug: Targeted Therapy Agent
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004255
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02966314
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
Study: NCT03784378
Drug: RXDX-105
Approvals — FDA: no, EMA: no, PMDA: no
Description: RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
Study: NCT01179295
Drug: BAY86-9766
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY86-9766 30 mg twice a day (bid).
Study: NCT01179295
Drug: BAY86-9766
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY86-9766 50 mg twice a day (bid).
Study: NCT01179295
Drug: BAY86-9766
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY86-9766 100 mg once a day (od)
Study: NCT01179295
Drug: BAY86-9766
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY86-9766 60 mg once a day (od)
Study: NCT04122196
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
Study: NCT01929083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive oral placebo two capsules once daily every evening for 7 days
Study: NCT01075087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral TAP block using sterile normal saline.
Study: NCT02331576
Drug: rocaine
Normalized name: Procaine
DrugBank: Procaine (DB00721)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02331576
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01829048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Q12h
Study: NCT01937312
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo comparator
Study: NCT01937312
Drug: Prostaglandin analogue
Normalized name: Prostaglandin analogue
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03723447
Drug: Bupivacaine/epinephrine/dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
Study: NCT02656888
Drug: Irlanda-1-Association
Approvals — FDA: no, EMA: no, PMDA: no
Description: For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
Study: NCT02656888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
Study: NCT01175512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
Study: NCT01608334
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
Study: NCT01608334
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
Study: NCT04401059
Drug: First or third generation EGFR-TKIs
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: refer to the drug label.
Study: NCT00326820
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00326820
Drug: Zolendronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
Study: NCT00312520
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01307423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03736044
Drug: TNF-blockers suspension in patients with rheumatoid arthritis
Approvals — FDA: no, EMA: no, PMDA: no
Description: in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
Study: NCT00942006
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg bid, 14 days
Study: NCT02213718
Drug: sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
Study: NCT01497392
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02687269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive Placebo twice daily in the three days before surgery
Study: NCT04438421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will then be given a placebo product to be used twice a day after meals and after normal oral hygiene procedures. Next, the subjects will be re-evaluated after 3 days and after one month.
Study: NCT02053974
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone
Study: NCT01794780
Drug: theophylline based treatment
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: theophylline based treatment
Study: NCT01794780
Drug: Other treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments
Study: NCT01400737
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
Study: NCT01400737
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
Study: NCT03567655
Drug: Farlutal tab. 500mg/ Pfizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxyprogesterone Acetate
Study: NCT01874483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01772134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder, Placebo
Study: NCT00138840
Drug: STA-5326 mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02721862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
Study: NCT01440101
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00763893
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
Study: NCT02279511
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 500 mL of saline solution. (IV)
Study: NCT01982630
Drug: MK-8521
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01982630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04396587
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil(0.1μg/kg) was administered before anesthesia induction.
Study: NCT04396587
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 10ml
Study: NCT00160927
Drug: actylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04439786
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group will be given the same volume of saline.
Study: NCT03877406
Drug: Hypoglycemics Oral
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose escalation of hypoglycemics oral
Study: NCT02441530
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00303810
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00303810
Drug: high-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00303810
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00448461
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison between heparin and bivalirudin
Study: NCT02725502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
Study: NCT00761215
Drug: TR-701 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral TR-701 200 mg for 5 to 7 days
Study: NCT00761215
Drug: TR-701 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral TR-701 300 mg for 5 to 7 days
Study: NCT00761215
Drug: TR-701 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-701 400 mg for 5 to 7 days
Study: NCT02885181
Drug: GS-9876 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered orally once daily
Study: NCT03486730
Drug: BT1718
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. This stage will have 3 to 6 patient cohorts until the recommended dose is established. The expansion phase will consist of two or more expansion cohorts to include tumour types known to commonly over-express MT1-MMP and where MT1-MMP overexpression is confirmed during prospective and retrospective (in appropriate patients) selection at enrolment. A squamous NSCLC and basket cohort will include approximately 16 patients each with high MT1-MMP levels. In the expansion cohorts BT1718 will be administered intravenously at the once weekly RP2D established in Phase I, Stage 2.
Study: NCT02885181
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Background therapy with methotrexate administered orally or parenterally once weekly
Study: NCT00513279
Drug: GSK618334
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
Study: NCT02280811
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
Study: NCT03443024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution administered subcutaneously.
Study: NCT05368675
Drug: medication for opioid use disorder
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an open-label study. The project proposes to enroll up to 500 opiate dependent individuals entering Medication Assisted Treatment (Methadone or buprenorphine/naloxone) at Go Vap Clinic, HCMC, Vietnam. All participants who appear to meet inclusion criteria and who express interest in drug treatment will be invited to be screened for participation in the research. All participants will receive BDRC sessions (weekly for 12 weeks, monthly thereafter until week 52).
Study: NCT01201499
Drug: Continuous IV remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
Study: NCT01645761
Drug: Endonase
Normalized name: INCONTINENCE DEVICE MALE C3 LARGE ENDOCARE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI- based triple therapy with endonase
Study: NCT04232449
Drug: PREDNISON Galepharm Tabl. 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone
Study: NCT04232449
Drug: placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 daily- doses of placebo (2 tablets)
Study: NCT00004829
Drug: tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03949673
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study: NCT03949673
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study: NCT03949673
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study: NCT03949673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
Study: NCT00033735
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
Study: NCT04244825
Drug: Control: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 150 mg capsules '00' size (PO) BID
Study: NCT01568216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT01938859
Drug: Shuganjieyu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
Study: NCT00513279
Drug: GSK618334 matching placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
Study: NCT04237649
Drug: KAZ954
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAZ954 will be administered in every arm.
Study: NCT03560362
Drug: Bupivacaine / Epinephrine
Normalized name: bupivacaine / epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01501487
Drug: PTH followed by dose dense AC of FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel.
Study: NCT01295333
Drug: The initiation of LT4 as soon as the first biological signs of hypothyroidism.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079727
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02079727
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04700267
Drug: GLPG3970 film-coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 for oral administration
Study: NCT03095092
Drug: BIA 6-512 400 mg
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
Study: NCT01779609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no